Sunday, 20 September 2026European Markets

AFFLUENT MEDICAL Stock Was 15.22% Up Before The Weekend

Loading stream...

(vianews) - the market ended the session with affluent medical (afme.pa) jumping 15.22% to €2.12 on friday, after five successive sessions in a row of gains. cac 40 slid 0.03% to €7,568.82, following the last session's downward trend on what was a somewhat negative trend trading session today.

affluent medical's last close was €1.84, 43.82% under its 52-week high of €3.28.

about affluent medical

affluent medical sa develops minimally invasive medical devices for the treatment of heart and vascular diseases in france. it develops kardiozis technology for the treatment of abdominal aortic aneurysm; kalios and epygon implants to treat mitral insufficiency; and artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. the company was founded in 2011 and is based in aix-en-provence, france.

earnings per share

as for profitability, affluent medical has a trailing twelve months eps of €-0.65.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -39.36%.

yearly top and bottom value

affluent medical's stock is valued at €2.12 at 21:30 est, way under its 52-week high of €3.28 and way higher than its 52-week low of €1.10.

revenue growth

year-on-year quarterly revenue growth declined by 25.8%, now sitting on 1.34m for the twelve trailing months.

volatility

affluent medical's last week, last month's, and last quarter's current intraday variation average was 9.53%, 2.43%, and 2.60%.

affluent medical's highest amplitude of average volatility was 9.53% (last week), 3.32% (last month), and 2.60% (last quarter).

moving average

affluent medical's value is way higher than its 50-day moving average of €1.23 and way higher than its 200-day moving average of €1.48.

more news about affluent medical (afme.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com